Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 14, Issue 8, Pages 365-370Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2003.08.002
Keywords
-
Categories
Funding
- NICHD NIH HHS [P50 HD044405, U54 HD34449, P50 HD44405] Funding Source: Medline
Ask authors/readers for more resources
Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic and reproductive disorder. It is associated with substantial defects in insulin action and secretion that confer a markedly increased risk for type 2 diabetes mellitus. Insulin resistance modifies reproductive function both by the direct actions of insulin on steroidogenesis and by disruption of insulin signaling pathways in the central nervous system. These insights have led to a new therapy for PCOS with insulin-sensitizing agents. Hyperandrogenemia and insulin resistance cluster in PCOS families, consistent with a genetic susceptibility to these abnormalities. There is evidence for both linkage and association of the hyperandrogenemia phenotype with an allele of a marker locus on chromosome 19, in the region of the gene encoding the insulin receptor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available